Article

Osteoarthritis (OA) is the most common cause of musculoskeletal disability in
elderly individuals, and it places an enormous economic burden on society.
Management of OA is primarily focused on palliative relief by using agents such
as nonsteroidal anti-inflammatory drugs and analgesics. However, such an approach
is limited by a narrow therapeutic focus that fails to address the progressive
and multimodal nature of OA. Given the favorable safety profile of most
nutritional interventions, identifying disease-modifying nutritional agents
capable of improving symptoms and also preventing, slowing, or even reversing the
degenerative process in OA should remain an important paradigm in translational
and clinical research. Applying advances in nutritional science to
musculoskeletal medicine remains challenging, given the fluid and dynamic nature
of the field, along with a rapidly developing regulatory climate over
manufacturing and commerce requirements. The aim of this article is to review the
available literature on effectiveness and potential mechanism of macronutrients
for OA, with a focus on the following: long-chain omega-3 essential fatty acids
eicosapentaenoic acid and docosahexaenoic acid, functional omega-6 fatty acid
gamma-linolenic acid, and macronutrient composition of background diet. There
also is a discussion about the concept of rational polysupplementation via the
strategic integration of multiple nutraceuticals with potential complementary
mechanisms for improving outcomes in OA. As applied nutritional science evolves,
it will be important to stay on the forefront of proteomics, metabolomics,
epigenetics, and nutrigenomics, because they hold enormous potential for
developing novel therapeutic and prognostic breakthroughs in many areas of
medicine, including OA.
CI - Copyright (c) 2012 American Academy of Physical Medicine and Rehabilitation.
Published by Elsevier Inc. All rights reserved.

Langue : ANGLAIS